Levobetaxolol

Levobetaxolol Overview

Levobetaxolol is an organic, optically active S-enantiomer derivative of betaxolol. Chemically, it belongs to the class of organic compounds known as tyrosols and derivatives within the phenols sub-class of benzenoids. Structurally, it consists of a 4-(2-cyclopropylmethoxyethyl)phenol core etherified to an (S)-1-(isopropylamino)propan-2-ol side chain, possessing a molecular weight of 307.43 g/mol.

What Is Levobetaxolol and How Does It Work?

Levobetaxolol acts primarily through selective blockade of ciliary body beta-1-adrenergic receptors to inhibit adenylate cyclase and intracellular cAMP generation, driving suppression of active aqueous humor secretion by the non-pigmented ciliary epithelium and sustained intraocular pressure reduction.

Is Levobetaxolol FDA Approved?

Levobetaxolol hydrochloride 0.5% ophthalmic suspension was approved by the US FDA in February 2000 under the trade name Betaxon. Its current regulatory status is FDA Approved (Brand Discontinued); while the original brand name product Betaxon was discontinued by the manufacturer for commercial reasons, the approval remains established in FDA pharmacopeial records.

What Was/Is Levobetaxolol Used For?

• Reduction of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma.
• Lowering intraocular pressure in patients with ocular hypertension at risk for optic nerve damage.
• Alternative ocular hypotensive monotherapy for glaucoma patients with mild reactive airway disease who cannot tolerate non-selective beta-blockers like timolol.

Before Taking Levobetaxolol: Contraindications & Precautions

Do not administer Levobetaxolol to patients with a known severe hypersensitivity to levobetaxolol, betaxolol, beta-adrenergic antagonists, or formulation excipients (such as benzalkonium chloride). It is strictly contraindicated in patients with severe sinus bradycardia, second- or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock, as systemic absorption can worsen cardiac conduction. Exercise caution in patients with asthma, chronic obstructive pulmonary disease (COPD), severe sinus node dysfunction, diabetes mellitus (beta-blockers mask hypoglycemia symptoms such as tachycardia), or hyperthyroidism.

Who Should Not Take Levobetaxolol?

• Individuals with known severe hypersensitivity or allergy to Levobetaxolol or beta-blockers.
• Patients with sinus bradycardia, second- or third-degree AV block, or overt heart failure.
• Patients in cardiogenic shock.
• Patients with severe reactive airway disease or uncontrolled severe asthma.

Levobetaxolol, Pregnancy & Safety

Topical ophthalmic instillation yields low systemic plasma levels (Cmax < 1 ng/mL). However, systemic beta-blocker absorption during pregnancy can cause fetal or neonatal bradycardia, hypoglycemia, and respiratory depression. Animal reproduction studies evaluating systemic levobetaxolol demonstrated delayed fetal skeletal ossification at high oral doses. It is classified as Pregnancy Category C. Levobetaxolol should be used during pregnancy only if the potential maternal benefit justifies the potential fetal risk. Beta-blockers are excreted in human breast milk; exercise caution when administering to nursing mothers.

Tell Your Doctor Before Taking Levobetaxolol

Inform your ophthalmologist or physician if you have a history of heart failure, slow heart rate, heart block, asthma, COPD, diabetes, thyroid disease, or myasthenia gravis, or if you are scheduled for elective surgery requiring general anesthesia.

Levobetaxolol Dosage & Administration

Formulated as a sterile ophthalmic suspension (0.5% w/v [5 mg/mL] levobetaxolol hydrochloride).

Levobetaxolol dosing requires twice-daily topical application.

Standard Levobetaxolol Dosing

• Ophthalmic IOP-Lowering Dosing (Adults & Elderly): Instill 1 drop of 0.5% Levobetaxolol suspension into the conjunctival sac of the affected eye(s) twice daily (every 12 hours).
• Combination Topical Therapy Dosing: If using more than one topical eye drop, separate instillation times by at least 5 to 10 minutes to prevent washout.
• Shake Well Before Use: Because it is formulated as a micro-suspension, the bottle must be shaken thoroughly before each dose to ensure uniform active drug distribution.

How Was/Is Levobetaxolol Administered

• Shake the bottle well. Tilt head back, pull lower eyelid down to form a pouch, hold dropper bottle vertically, and instill 1 drop into the pouch without touching the eye or eyelid.
• Perform Nasolacrimal Occlusion: Close the eye gently and press finger firmly against the inner corner of the eye (lacrimal sac) for 1 to 2 minutes post-instillation to decrease systemic drug drainage down the nasolacrimal duct.
• Remove soft contact lenses prior to instillation; wait at least 15 minutes before reinserting lenses.

Levobetaxolol Clinical Efficacy & Research

In clinical ophthalmology and glaucoma research, Levobetaxolol is recognized as a potent cardioselective ocular hypotensive agent. Multi-center double-blind randomized controlled clinical trials comparing Levobetaxolol 0.5% twice daily to racemic betaxolol 0.5% and timolol 0.5% in patients with open-angle glaucoma or ocular hypertension demonstrate a mean IOP reduction of 3.5 to 6.0 mmHg (18% to 25% baseline reduction) over 3 to 12 months. Clinical comparative studies establish that Levobetaxolol provides equivalent intraocular pressure lowering to racemic betaxolol while utilizing half the total active drug concentration of the effective S-enantiomer. Furthermore, pulmonary function trials confirm that Levobetaxolol causes significantly fewer reductions in forced expiratory volume in one second (FEV1) in patients with reactive airway disease compared to non-selective beta-blockers like timolol.

Levobetaxolol Side Effects & Safety Profile

Levobetaxolol exhibits a favorable ocular and cardioselective safety profile. Safety hazards stem primarily from systemic absorption in patients with severe underlying cardiac or respiratory disease.

Adverse effects are localized predominantly to the ocular surface, with rare systemic effects.

Common Levobetaxolol Side Effects

• Ophthalmic Application (10% to 11% incidence): Transient ocular burning, stinging, or discomfort upon instillation.
• Ophthalmic Application (1% to 5% incidence): Transient blurred vision, dry eye sensation, ocular itching, punctate keratitis, and foreign body sensation.

Serious Levobetaxolol Adverse Events

• Systemic Cardiovascular Reactions: Severe bradycardia, hypotension, heart block, syncope, and exacerbation of congestive heart failure secondary to systemic absorption.
• Systemic Respiratory Reactions: Bronchospasm, severe asthmatic attacks, and dyspnea in patients with sensitive or hyper-reactive airways.
• Masking of Hypoglycemia & Hyperthyroidism: Blunting of sympathetic tachycardia during acute insulin-induced hypoglycemia or thyrotoxicosis.
• Severe Ocular Hypersensitivity: Allergic conjunctivitis, blepharitis, or corneal epithelial breakdown.

Managing Levobetaxolol Side Effects

If severe ocular burning or persistent blurred vision occurs, evaluate corneal integrity using fluorescein staining. If systemic bradycardia or wheezing develops, discontinue Levobetaxolol immediately and switch to a non-beta-blocker antiglaucoma class (such as a carbonic anhydrase inhibitor or prostaglandin analogue).

Levobetaxolol Drug Interactions & What to Avoid

Levobetaxolol displays important pharmacodynamic interactions with oral beta-blockers, calcium channel blockers, and catecholamine-depleting agents.

Co-administration with specific drug classes accelerates systemic hypotensive or bradycardic risks.

Levobetaxolol Drug-Drug Interactions

• Oral Beta-Adrenergic Blockers (Propranolol, Atenolol, Metoprolol): Additive systemic beta-blockade; co-administration increases risks of severe bradycardia and hypotension.
• Calcium Channel Blockers (Verapamil, Diltiazem) & Digitalis: Co-administration enhances AV node conduction delay, predisposing to severe heart block and bradycardia.
• Catecholamine-Depleting Drugs (Reserpine): Additive sympathetic depletion, causing severe hypotension, marked bradycardia, and vertigo.
• CYP2D6 Inhibitors (Quinidine, Fluoxetine, Paroxetine): Levobetaxolol is metabolized partly by CYP2D6; potent CYP2D6 inhibitors increase systemic levobetaxolol plasma exposure.

Levobetaxolol, Food & Alcohol

Systemic food interactions do not occur with topical ophthalmic administration. Alcohol consumption does not directly alter topical ophthalmic levobetaxolol pharmacokinetics.

Levobetaxolol: Missed Dose, Overdose & Storage

Proper handling of Levobetaxolol involves consistent twice-daily instillation and proper solution storage. Overdose is rare with topical application.

Adherence to proper storage parameters prevents suspension settling and bacterial contamination.

Missed Dose of Levobetaxolol

Instill the missed drop as soon as remembered, unless near the time for the next scheduled dose. Skip the missed dose if near the next dose; do not instill double drops to make up for a missed dose.

Levobetaxolol Overdose & Emergency

Topical ocular overdose is self-limiting due to excess liquid flushing out of the conjunctival sac. Accidental oral ingestion of an entire 5 mL bottle of 0.5% suspension yields 25 mg of levobetaxolol hydrochloride, which can cause systemic beta-blockade (bradycardia, hypotension, bronchospasm, and sedation). Emergency management includes gastric lavage or activated charcoal if presented early, supportive IV fluids, atropine for severe bradycardia, and IV glucagon for refractory beta-blocker toxicity.

How to Store Levobetaxolol

Store unopened and opened Levobetaxolol 0.5\% ophthalmic suspension bottles at controlled room temperature between 8°C and 25°C (46°F to 77°F). Protect strictly from freezing and direct light exposure. Keep bottle tightly closed when not in use. Keep out of reach of children.

Levobetaxolol Patient Management & Monitoring

Clinical oversight for patients taking Levobetaxolol focuses on measuring intraocular pressure, checking baseline pulse/blood pressure, and monitoring respiratory status.

Regular clinical tracking ensures successful IOP control without systemic cardiovascular or pulmonary compromise.

Tests Before Starting Levobetaxolol

Baseline intraocular pressure (IOP) measurement via Goldmann applanation tonometry; baseline pulse rate and systemic blood pressure; baseline optic nerve head examination and visual field testing; baseline respiratory history screening for asthma/COPD.

Monitoring During Levobetaxolol Treatment

Re-evaluating IOP at 4 weeks and 12 weeks post-initiation; monitoring pulse rate and blood pressure at clinical visits; inspecting cornea and conjunctiva for local tolerance; performing annual visual field and optic nerve OCT scans.

Levobetaxolol Do’s and Don’ts

• Do shake the ophthalmic suspension bottle thoroughly before applying each drop.
• Do press the inner corner of your eye for 1 to 2 minutes after applying drops to stop systemic absorption.
• Do remove soft contact lenses before instilling drops and wait 15 minutes before reinserting them.
• Do not touch the dropper tip to your eye, fingers, or any surface to avoid bacterial contamination.
• Do not double your dose if you miss an application.
• Do not stop using your eye drops without consulting your ophthalmologist, as eye pressure can rise rapidly.

Frequently Asked Questions

References

• DrugBank Database – Levobetaxolol Clinical Profile (DB09351)
• Classyfire Database – Tyrosols and Derivatives / Benzenoids Taxonomy Profile
• US Food and Drug Administration (FDA) – Betaxon (Levobetaxolol Hydrochloride Ophthalmic Suspension) Prescribing Information

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.